1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BofA Securities Upgrades Moderna to Neutral From Underperform, Adjusts Price Target to $180 From $135

01/21/2022 | 09:29am EDT


© MT Newswires 2022
All news about MODERNA, INC.
12:20pAs COVID cases rise, U.S. health officials mull widening additional booster eligibility
RE
08:10aModerna, International AIDS Vaccine Initiative to Start Volunteer Screening for Phase 1..
MT
04:51aPiper Sandler Adjusts Moderna's Price Target to $214 From $348, Reiterates Overweight R..
MT
03:01aFrom storage to transport, hurdles to getting COVID vaccine to N.Koreans
RE
05/17TRANSCRIPT : Moderna, Inc. - Special Call
CI
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
05/13MODERNA, INC. Change in Directors or Principal Officers, Financial Statements and Exhi..
AQ
05/13SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/13KHF Welcomes the African Medicines Agency Treaty Cabinet Approval
AQ
05/13Swiss Medical Regulator Approves Moderna's Covid-19 Vaccine for 6-11-Year-Olds
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 22 022 M - -
Net income 2022 11 474 M - -
Net cash 2022 18 522 M - -
P/E ratio 2022 5,24x
Yield 2022 -
Capitalization 56 593 M 56 593 M -
EV / Sales 2022 1,73x
EV / Sales 2023 3,43x
Nbr of Employees 2 700
Free-Float 90,6%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 142,28 $
Average target price 216,12 $
Spread / Average Target 51,9%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-43.98%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-26.74%39 122
SEAGEN INC.-5.21%26 976
ICON PUBLIC LIMITED COMPANY-32.47%17 002
ALNYLAM PHARMACEUTICALS, INC.-26.37%15 622